{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:53:44Z","timestamp":1783511624864,"version":"3.55.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Although treatment-related lymphopenia (TRL) is common and associated with poorer survival in multiple solid malignancies, few data exist for anal cancer. We evaluated TRL and its association with survival in patients with anal cancer treated with chemoradiation (CRT).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>A retrospective analysis of 140 patients with nonmetastatic anal squamous cell carcinoma (SCC) treated with definitive CRT was performed. Total lymphocyte counts (TLC) at baseline and monthly intervals up to 12 months after initiating CRT were analyzed. Multivariable Cox regression analysis was performed to evaluate the association between overall survival (OS) and TRL, dichotomized by grade (G)4 TRL (&amp;lt;0.2k\/\u03bcL) 2 months after initiating CRT. Kaplan-Meier and log-rank tests were used to compare OS between patients with versus without G4 TRL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Median time of follow-up was 55 months. Prior to CRT, 95% of patients had a normal TLC (&amp;gt;1k\/\u03bcL). Two months after initiating CRT, there was a median of 71% reduction in TLC from baseline and 84% of patients had TRL: 11% G1, 31% G2, 34% G3, and 8% G4. On multivariable Cox model, G4 TRL at two months was associated with a 3.7-fold increased risk of death. On log-rank test, the 5-year OS rate was 32% in the cohort with G4 TRL versus 86% in the cohort without G4 TRL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>TRL is common and may be another prognostic marker of OS in anal cancer patients treated with CRT. The association between TRL and OS suggests an important role of the host immunity in anal cancer outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>This is the first detailed report demonstrating that standard chemoradiation (CRT) commonly results in treatment-related lymphopenia (TRL), which may be associated with a poorer overall survival (OS) in patients with anal squamous cell carcinoma. The association between TRL and worse OS observed in this study supports the importance of host immunity in survival among patients with anal cancer. These findings encourage larger, prospective studies to further investigate TRL, its predictors, and its relationship with survival outcomes. Furthermore, the results of this study support ongoing efforts of clinical trials to investigate the potential role of immunotherapy in anal cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0759","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T16:01:42Z","timestamp":1600704102000},"page":"1015-1022","source":"Crossref","is-referenced-by-count":17,"title":["Chemoradiation-Related Lymphopenia and Its Association with Survival in Patients with Squamous Cell Carcinoma of the Anal Canal"],"prefix":"10.1093","volume":"25","author":[{"given":"Grace","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinayak","family":"Muralidhar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devarati","family":"Mitra","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora K.","family":"Horick","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Biostatistics Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Eyler","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore S.","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine C.","family":"Drapek","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill N.","family":"Allen","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence S.","family":"Blaszkowsky","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Giantonio","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna R.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Ryan","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Clark","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Y.","family":"Wo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,12]]},"reference":[{"key":"2021122511342425400_onco13488-bib-0001","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1172\/JCI31405","article-title":"Immune surveillance of tumors","volume":"117","author":"Swann","year":"2007","journal-title":"J Clin Invest"},{"key":"2021122511342425400_onco13488-bib-0002","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1158\/0008-5472.CAN-08-3845","article-title":"Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas","volume":"69","author":"Ray-Coquard","year":"2009","journal-title":"Cancer Res"},{"key":"2021122511342425400_onco13488-bib-0003","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1258\/ebm.2011.011007","article-title":"Tumor-infiltrating immune cells and prognosis: The potential link between conventional cancer therapy and immunity","volume":"236","author":"Jochems","year":"2011","journal-title":"Exp Biol Med (Maywood)."},{"key":"2021122511342425400_onco13488-bib-0004","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/bjc.2015.448","article-title":"Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer","volume":"114","author":"Gilbert","year":"2016","journal-title":"Br J Cancer"},{"key":"2021122511342425400_onco13488-bib-0005","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2307\/3577549","article-title":"Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay","volume":"123","author":"Nakamura","year":"1990","journal-title":"Radiat Res"},{"key":"2021122511342425400_onco13488-bib-0006","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.adro.2018.08.014","article-title":"Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors","volume":"3","author":"Ellsworth","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"2021122511342425400_onco13488-bib-0007","doi-asserted-by":"crossref","first-page":"E123","DOI":"10.1016\/j.ijrobp.2016.06.2512","article-title":"Chemoradiation-related lymphopenia is common among glioblastoma patients and is associated with worse progression-free and overall survival","volume":"96","author":"Rahman","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122511342425400_onco13488-bib-0008","first-page":"3541","article-title":"Prognostic value of severe lymphopenia during pelvic concurrent chemoradiotherapy in cervical cancer","volume":"36","author":"Cho","year":"2016","journal-title":"Anticancer Res"},{"key":"2021122511342425400_onco13488-bib-0009","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijrobp.2017.05.037","article-title":"Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy","volume":"99","author":"Davuluri","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4 suppl","key":"2021122511342425400_onco13488-bib-0010","article-title":"The impact of proton beam therapy on blood cell count nadir during neoadjuvant chemoradiation therapy for esophageal cancer","volume":"35","author":"Shiraishi","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2021122511342425400_onco13488-bib-0011","doi-asserted-by":"crossref","first-page":"18513a","DOI":"10.1200\/jco.2015.33.15_suppl.e18513","article-title":"Lymphopenia as a predictor of survival in chemoradiation (CRT)-treated stage III non-small cell lung cancer (NSCLC)","volume":"33","author":"Yellu","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021122511342425400_onco13488-bib-0012","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1002\/hed.23535","article-title":"Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer","volume":"36","author":"Campian","year":"2014","journal-title":"Head Neck"},{"key":"2021122511342425400_onco13488-bib-0013","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/07357907.2013.767342","article-title":"Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer","volume":"31","author":"Campian","year":"2013","journal-title":"Cancer Invest"},{"key":"2021122511342425400_onco13488-bib-0014","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3109\/07357907.2012.700987","article-title":"The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas","volume":"30","author":"Balmanoukian","year":"2012","journal-title":"Cancer Invest"},{"key":"2021122511342425400_onco13488-bib-0015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/COC.0b013e3182940ff9","article-title":"The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma","volume":"38","author":"Wild","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"2021122511342425400_onco13488-bib-0016","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ygyno.2015.11.013","article-title":"Lymphopenia and its association with survival in patients with locally advanced cervical cancer","volume":"140","author":"Wu","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2021122511342425400_onco13488-bib-0017","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11060-015-2037-1","article-title":"Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma","volume":"127","author":"Mendez","year":"2016","journal-title":"J Neurooncol"},{"key":"2021122511342425400_onco13488-bib-0018","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/1097-0142(19830515)51:10<1826::AID-CNCR2820511012>3.0.CO;2-L","article-title":"Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal","volume":"51","author":"Nigro","year":"1983","journal-title":"Cancer"},{"key":"2021122511342425400_onco13488-bib-0019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122511342425400_onco13488-bib-0020","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","article-title":"Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"2021122511342425400_onco13488-bib-0021","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.ijrobp.2007.08.074","article-title":"Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy","volume":"70","author":"Mell","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122511342425400_onco13488-bib-0022","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12094-016-1504-2","article-title":"Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer","volume":"19","author":"Franco","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"2021122511342425400_onco13488-bib-0023","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.radonc.2013.08.002","article-title":"p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: Correlation with outcomes following chemo-radiotherapy","volume":"109","author":"Gilbert","year":"2013","journal-title":"Radiother Oncol"},{"key":"2021122511342425400_onco13488-bib-0024","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.radonc.2014.11.013","article-title":"Influence of human papillomavirus and p16(INK4a) on treatment outcome of patients with anal cancer","volume":"113","author":"Koerber","year":"2014","journal-title":"Radiother Oncol"},{"key":"2021122511342425400_onco13488-bib-0025","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.28979","article-title":"Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy","volume":"136","author":"R\u00f6del","year":"2015","journal-title":"Int J Cancer"},{"key":"2021122511342425400_onco13488-bib-0026","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/COC.0000000000000343","article-title":"Programmed cell death-ligand 1 (PD-L1) expression in anal cancer","volume":"41","author":"Govindarajan","year":"2018","journal-title":"Am J Clin Oncol"},{"key":"2021122511342425400_onco13488-bib-0027","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/annonc\/mdx029","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal","volume":"28","author":"Ott","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122511342425400_onco13488-bib-0028","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): A multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021122511342425400_onco13488-bib-0029","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","author":"U.S. Department of Health and Human Services","year":"2017"},{"key":"2021122511342425400_onco13488-bib-0030","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1080\/07357907.2018.1499028","article-title":"Severe treatment-related lymphopenia in patients with newly diagnosed rectal cancer","volume":"36","author":"Campian","year":"2018","journal-title":"Cancer Invest"},{"key":"2021122511342425400_onco13488-bib-0031","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.3747\/co.21.1903","article-title":"One compared with two cycles of mitomycin C in chemoradiotherapy for anal cancer: Analysis of outcomes and toxicity","volume":"21","author":"Yeung","year":"2014","journal-title":"Curr Oncol"},{"key":"2021122511342425400_onco13488-bib-0032","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1158\/1078-0432.CCR-11-0774","article-title":"Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide","volume":"17","author":"Grossman","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2021122511342425400_onco13488-bib-0033","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2016-03-708594","article-title":"Antibiotics impair murine hematopoiesis by depleting the intestinal microbiota","volume":"129","author":"Josefsdottir","year":"2017","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2019-0759","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0759","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0759","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/12\/1015\/41920876\/oncolo_25_12_1015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/12\/1015\/41920876\/oncolo_25_12_1015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:35:23Z","timestamp":1640432123000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/12\/1015\/6443992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,12]]},"references-count":33,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,9,12]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0759","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,9,12]]}}}